🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT07096258
Recruiting Observational

EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

NCT07096258 · tracked via the Priya Life Science Spain tracker
Sponsor
Hedera Dx SA
Phase
Observational
Started
2024-06-01
Last updated
2025-07-31

Condition(s) studied

NSCLC (Advanced Non-small Cell Lung Cancer)

Study summary

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease. * Intention-to-initiate first-line tumour therapy for this advanced disease. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * At least 18 years of age on the day of signing informed consent, and capable of signing informed consent. Exclusion Criteria: * Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Université de Lorraine Nancy Lorraine Recruiting
University of Naples "Federico II" Naples Italy Recruiting
General Universitario Gregorio Marañon Madrid Spain Not Yet Recruiting
Hôpitaux Universitaires Genève Geneva Canton of Geneva Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07096258 on ClinicalTrials.gov ↗ ← All trials in Spain